|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | TOTAL SYNTHESIS OF CLAUSENAMIDE显示文摘TOTAL SYNTHESIS OF CLAUSENAMIDETOTALSYNTHESISOFCLAUSENAMIDE￥ErChangRAO;HaoHONG;JiaChongCHENG;GuangZhongYANG;HanSenLIN;andLian... | Er Chang RAO Hao HONG Jia Chong CHENG Guang Zhong YANG Han Sen LIN andLiang HUANG(Institute of Mareia Medica. Chinese Academy of Medical Sciences1 Xian Nong Tan St .Beijing 100050) | 1994 | Chinese Chemical Letters1994，5，4： | 4 |
| 2 | Cellular and extracellular markers of hemangioma显示文摘 | Tan ST Velickovic M Ruger MB | 2000 | Plast Reconstr Surg2000，106，： | 2 |
| 3 | Cilostazol for secondary stroke prevention:systematic review and meta-analysis显示文摘Background Stroke is one of the leading causes of death worldwide.Cilostazol,an antiplatelet and phosphodiesterase 3 inhibitor,has not been clearly established for ischaemic stroke use.We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention.Methods MEDLINE,EMBASE,Cochrane Library,Web of Science and ClinicalTrials.gov were searched from inception to 25 September 2020,for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo,in patients with ischaemic stroke.Version 2 of the Cochrane risk-of-bias tool for randomised trials(RoB 2)was used to assess study quality.This meta-analysis was reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)statement.Results Eighteen randomised trials comprising 11429 participants were included in this meta-analysis.Most trials possessed low risk of bias and were of low heterogeneity.Cilostazol significantly reduced the rate of ischaemic stroke recurrence(risk ratio,RR=0.69,95%CI 0.58 to 0.81),any stroke recurrence(RR=0.64,95%CI 0.54 to 0.74)and major adverse cardiovascular events(RR=0.67,95%CI 0.56 to 0.81).Cilostazol did not significantly decrease mortality(RR=0.90,95%CI 0.64 to 1.25)or increase the rate of good functional outcome(Modified Rankin Scale score of 0–1;RR=1.07,95%CI 0.95 to 1.19).Cilostazol demonstrated favourable safety profile,significantly reducing the risk of intracranial haemorrhage(RR=0.46,95%CI 0.31 to 0.68)and major haemorrhagic events(RR=0.49,95%CI 0.34 to 0.70).Conclusions Cilostazol demonstrated superior efficacy and safety profiles compared with traditional antiplatelet regimens such as aspirin and clopidogrel for secondary stroke prevention but does not appear to affect functional outcomes.Future randomised trials can be conducted outside East Asia,or compare cilostazol with a wider range of antiplatelet agents. | Choon Han Tan Andrew GR Wu Ching-Hui Sia Aloysius ST Leow Bernard PL Chan Vijay Kumar Sharma Leonard LL Yeo Benjamin YQ Tan | 2021 | Stroke & Vascular Neurology2021，6，3： | 2 |
| 4 | Cellular and extracellular markers of hemangioma显示文摘 | Tan ST Velickovic M Ruger BM | 2000 | Plast Reconstr Surg2000，106，3： | 1 |
| 5 | Low dose propranolol for infantile haemangioma 显示文摘 | Tan ST Itinteang T Leadbitter P | 2011 | J Plast Reconstr Aesthet Surg2011，64，3： | 1 |
| 6 | Oblique lumbar interbody fixation:a biomeehanieal study in human spines 显示文摘 | St Clair S Tan JS Lieberman I | 2012 | J Spinal Disord Teeh2012，25，4： | 1 |
| 7 | Haemogenic endothelium in infantile haemangioma显示文摘 | Itinteang T Tan ST Braseh H | 2010 | J Clin Pathol2010，63，11： | 1 |
| 8 | Low-dose propranolol for infan- tile haemangioma显示文摘 | Tan ST Itinteang T Leadbitter P | 2011 | J Hast Reconstr Aesthet Surg2011，64，： | 1 |
| 9 | Clusterin/apoJ expression during the development of hemangloma 显示文摘 | Hasan Q Ruger BM Tan ST | 2000 | Hum Pathol2000，31，6： | 1 |
| 10 | Cellular and extracellular markers of hemangioma显示文摘 | Tan ST Velickovic M Ruger MB | 2000 | Plast Reconstr Surg2000，106，3： | 1 |
| 11 | A novel in vitro human model of hemangioma显示文摘 | Tan ST Hasan Q Velickovic M | 2000 | Mod Pathol2000，13，1： | 1 |
| 12 | Expression ofcomponents of the renin-angiotensin system in proliferatinginfantile haemangioma may account for the propranolol-inducedaccelerated involution 显示文摘 | Itinteang T Brasch HD Tan ST | 2011 | J Plast Reconstr Aesthet Surg2011，64，6： | 1 |
| 13 | Cellular and extraeel- lular markers of hemangioma显示文摘 | Tan ST Velickovic M Ruger BM | 2000 | Plast Reconstr Surg2000，106，3： | 1 |
| 14 | A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma显示文摘 | Itinteang T Tan ST Guthrie S | 2011 | J Clin Pathol2011，64，10： | 1 |
| 15 | Correction of deformation- al auricular anomalies by moulding-results of a fast-track serv ice显示文摘 | Tan ST Wright A Hemphi11 A | 2003 | N Z Med J2003，116，1181： | 1 |
| 16 | Ceilular and extracellular markers of hemangioma显示文摘 | Tan ST Velickovic M Ruger M | 2000 | Plast Reconstr Surg2000，106，： | 1 |
| 17 | Mast cells and hemangioma显示文摘 | Tan ST Wallis RA He Y | 2004 | Plast Reconstr Surg2004，113，： | 1 |
| 18 | Analysis and design of interleaver mappings for iteratively decoded BICM 显示文摘 | Tan J Stüber G L | 2005 | IEEE Transactions on Wireless Communications2005，4，2： | 1 |
| 19 | Deep plane cervicofacial flap: a useful and versatile technique in head and neck surgery显示文摘 | Tan ST Mackilmon CA | 2006 | Head Neck2006，28，1： | 1 |
| 20 | Haemogenic endothelium in infantile haemangioma显示文摘 | Itinteang T Tan ST Brasch H | 2010 | J Clin Pathol2010，63，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员